Julian Harrison
Stock Analyst at BTIG
(4.63)
# 190
Out of 5,163 analysts
101
Total ratings
59.14%
Success rate
25.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Reiterates: Buy | $137 | $71.90 | +90.54% | 5 | Mar 16, 2026 | |
| ORKA Oruka Therapeutics | Reiterates: Buy | $73 | $40.00 | +82.50% | 5 | Mar 13, 2026 | |
| MAZE Maze Therapeutics | Reiterates: Buy | $46 | $50.21 | -8.38% | 5 | Mar 9, 2026 | |
| LQDA Liquidia | Maintains: Buy | $49 → $50 | $36.66 | +36.39% | 7 | Mar 5, 2026 | |
| TBPH Theravance Biopharma | Maintains: Buy | $40 → $21 | $13.78 | +52.39% | 5 | Mar 3, 2026 | |
| INVA Innoviva | Reiterates: Buy | $35 | $22.03 | +58.87% | 2 | Feb 26, 2026 | |
| AKBA Akebia Therapeutics | Maintains: Buy | $5 → $4 | $1.46 | +173.97% | 4 | Feb 25, 2026 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Buy | $150 | $115.50 | +29.87% | 5 | Feb 25, 2026 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $24 → $30 | $17.13 | +75.13% | 5 | Feb 23, 2026 | |
| SYRE Spyre Therapeutics | Reiterates: Buy | $70 | $39.89 | +75.48% | 5 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $17 | $5.78 | +194.12% | 3 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $151 | $73.25 | +106.14% | 4 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $1 | $0.39 | +159.07% | 3 | Jan 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $2.60 | +92.68% | 5 | Jan 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $38 | $13.49 | +181.69% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $42 → $44 | $7.39 | +495.40% | 2 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.69 | +271.75% | 2 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $61 | $28.68 | +112.69% | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $82 | $92.36 | -11.22% | 3 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $7.03 | +13.80% | 3 | Oct 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $15 | $3.92 | +282.65% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $13.92 | +101.15% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $15.80 | +153.16% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.02 | - | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $64.81 | - | 2 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $9 | $0.39 | +2,184.26% | 5 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $8 | $3.54 | +125.99% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.59 | +1,252.95% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.64 | +23,231.78% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $536.12 | - | 2 | Feb 11, 2022 |
Apogee Therapeutics
Mar 16, 2026
Reiterates: Buy
Price Target: $137
Current: $71.90
Upside: +90.54%
Oruka Therapeutics
Mar 13, 2026
Reiterates: Buy
Price Target: $73
Current: $40.00
Upside: +82.50%
Maze Therapeutics
Mar 9, 2026
Reiterates: Buy
Price Target: $46
Current: $50.21
Upside: -8.38%
Liquidia
Mar 5, 2026
Maintains: Buy
Price Target: $49 → $50
Current: $36.66
Upside: +36.39%
Theravance Biopharma
Mar 3, 2026
Maintains: Buy
Price Target: $40 → $21
Current: $13.78
Upside: +52.39%
Innoviva
Feb 26, 2026
Reiterates: Buy
Price Target: $35
Current: $22.03
Upside: +58.87%
Akebia Therapeutics
Feb 25, 2026
Maintains: Buy
Price Target: $5 → $4
Current: $1.46
Upside: +173.97%
ABIVAX Société Anonyme
Feb 25, 2026
Reiterates: Buy
Price Target: $150
Current: $115.50
Upside: +29.87%
MoonLake Immunotherapeutics
Feb 23, 2026
Maintains: Buy
Price Target: $24 → $30
Current: $17.13
Upside: +75.13%
Spyre Therapeutics
Feb 20, 2026
Reiterates: Buy
Price Target: $70
Current: $39.89
Upside: +75.48%
Feb 20, 2026
Reiterates: Buy
Price Target: $17
Current: $5.78
Upside: +194.12%
Feb 10, 2026
Maintains: Buy
Price Target: $118 → $151
Current: $73.25
Upside: +106.14%
Jan 16, 2026
Reiterates: Buy
Price Target: $1
Current: $0.39
Upside: +159.07%
Jan 8, 2026
Reiterates: Buy
Price Target: $5
Current: $2.60
Upside: +92.68%
Nov 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $13.49
Upside: +181.69%
Nov 14, 2025
Maintains: Buy
Price Target: $42 → $44
Current: $7.39
Upside: +495.40%
Nov 13, 2025
Reiterates: Buy
Price Target: $10
Current: $2.69
Upside: +271.75%
Nov 4, 2025
Reiterates: Buy
Price Target: $61
Current: $28.68
Upside: +112.69%
Oct 28, 2025
Reiterates: Buy
Price Target: $82
Current: $92.36
Upside: -11.22%
Oct 16, 2025
Reiterates: Buy
Price Target: $8
Current: $7.03
Upside: +13.80%
Oct 13, 2025
Maintains: Buy
Price Target: $55 → $15
Current: $3.92
Upside: +282.65%
Oct 9, 2025
Initiates: Buy
Price Target: $28
Current: $13.92
Upside: +101.15%
Sep 29, 2025
Reiterates: Buy
Price Target: $40
Current: $15.80
Upside: +153.16%
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $11.02
Upside: -
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $64.81
Upside: -
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $0.39
Upside: +2,184.26%
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $3.54
Upside: +125.99%
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $0.59
Upside: +1,252.95%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.64
Upside: +23,231.78%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $536.12
Upside: -